NCT06024499View on ClinicalTrials.gov

Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

March 31, 2026

Conditions
Atopic DermatitisAtopic Dermatitis EczemaAtopic Dermatitis of Scalp
Interventions
DRUG

HY209GEL Active

Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1

OTHER

Placebo

Placebo

Trial Locations (4)

10075

RECRUITING

Sadick Dermatology, New York

16133

RECRUITING

RAOOF MD Dermatology, Encino

21204

RECRUITING

Continental Clinical Solutions, LLC, Towson

35244

RECRUITING

Cahaba Dermatology Skin Health Center, Birmingham

Sponsors

Lead Sponsor

Shaperon
All Listed Sponsors
lead

Shaperon

INDUSTRY

NCT06024499 - Phase 2 Trial of HY209gel in Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter